Business people interacting to each other.

Bryan, Garnier & Co hires Phil Walker as Managing Director in its London Healthcare division

LONDON, October, 30  2017 – Bryan, Garnier & Co, the leading pan-European Investment Bank focusing on growth companies, is proud to announce the hiring of senior banker Phil Walker to join its European Healthcare division in London.

Phil Walker has advised on more than 60 successful transactions including IPOs, secondary fundraisings and M&A in the UK, Europe, Israel and the US. He joins Bryan, Garnier & Co as Managing Director UK Healthcare Corporate Finance.

Phil, British, is a corporate financier and equity capital markets investment banker with 20 years’ experience advising healthcare/life science and high growth technology companies.

Prior to joining Bryan, Garnier & Co, he was Head of Healthcare and Cleantech corporate finance at Zeus Capital Limited.  Previously, Phil was a Co-founder of investment banking boutique, Code Securities, which was acquired by Nomura. Prior to Code Securities, he spent five years as a specialist healthcare corporate financier in the WestLB Panmure Life Sciences Group, then Europe's leading healthcare investment bank. Phil qualified as a chartered accountant with Price Waterhouse in 1997.

Phil Walker comments, “I am delighted to have joined Bryan, Garnier & Co. The firm shares my focus and long-term commitment to the healthcare sector and I look forward to building Bryan Garnier’s UK healthcare business to strengthen further the firm’s leading position in continental Europe".

Olivier Garnier, Managing Partner, adds: “I am pleased to have Phil join us to help build our UK business. The quality and the depth of his experience within the UK healthcare community will be a great asset for the team.  Phil’s appointment comes after Dominic Wilson and Gary Waanders joined the firm in last month and aims to reinforce the Bryan, Garnier Healthcare franchise in London".

About Bryan, Garnier & Co

Bryan, Garnier & Co is a European, full-service growth-focused independent investment banking partnership founded in 1996. The firm provides equity research, sales and trading, private and public capital raising as well as M&A services to growth companies and their investors. It focuses on key growth sectors of the economy including Technology, Healthcare, Consumer and Business Services. Bryan, Garnier & Co is a fully registered broker dealer authorized and regulated by the FCA in Europe and the FINRA in the U.S. Bryan, Garnier & Co is headquartered in London, with additional offices in Paris, Munich, Stockholm, Oslo and Reykjavik as well as New York and Palo Alto. The firm is a member of the London Stock Exchange.

(www.bryangarnier.com)


business man handshake with effect global world map network link connection and graph chart of stock market graphic diagram, digital technology, internet communication, teamwork, partnership concept

Bryan, Garnier & Co strengthens its Investment Banking team with the hiring of Marc-Antoine Janny as Vice President

PARIS, October 17, 2017 – Bryan, Garnier & Co, the leading pan-European Investment Bank focusing on growth companies, is delighted to welcome back Marc-Antoine Janny to its European investment banking team, based in Paris.

With over eight years of corporate finance  experience in M&A and ECM, Marc-Antoine, will join the firm as Vice President and will be responsible for the origination and execution of private placement and M&A mandates for European growth companies, as well as help Bryan, Garnier & Co to leverage its footprint within its healthcare and TMT practices.

Marc-Antoine worked for Bryan, Garnier & Co as an M&A analyst from 2008 to 2011 when he left to join Michel Dyens & Co. He then founded Canary Street, the first European marketplace dedicated to the distribution of emerging designers in the home decor environment whose assets were acquired by Belgium-based e-commerce company Decovry. In 2015 he joined goetzpartners before moving back to Bryan, Garnier & Co as a Vice President.  During his career, he has developed a significant experience in M&A, ECM and fundraising transactions including: Capital increase of Airlinair (subsidiary of Air France), IPO of Integragen, disposal of Vemedia to Industri Kapital, disposal of Russia-based Ekomir Pharma to Valeant and the disposal of Italy-based Sharper Therapeutics to Gruppo Indena della Beffa.

Greg Revenu, Managing Partner, Paris comments: “I am delighted to welcome Marc-Antoine back to the Bryan, Garnier & Co investment banking team.  Marc-Antoine has an entrepreneurial mindset having successfully founded, funded, run and sold a start-up and as such brings with him a valuable perspective to best support the founders we advise”.

Marc-Antoine adds: “I am pleased to be back at Bryan, Garnier & Co and have a particular attachment to the firm and the great people working here. I started my career at the company and truly believe in its market positioning, strong track record and deep sector expertise in TMT and Healthcare sectors making it ideal to serve growth companies in Europe. I am looking forward to contributing to its future growth in the European market”.

Marc-Antoine holds a master in Finance from Grenoble Graduate School of Business and Singapore Management University.

About Bryan, Garnier & Co

Bryan, Garnier & Co is a European, full service growth-focused independent investment banking partnership founded in 1996. The firm provides equity research, sales and trading, private and public capital raising as well as M&A services to growth companies and their investors. It focuses on key growth sectors of the economy including Technology, Media & Telecoms, Healthcare, Smart Industries & Energy, Consumer, Brands & Retail and Business Services. Bryan, Garnier & Co is a fully registered broker dealer authorized and regulated by the FCA in Europe and the FINRA in the U.S. Bryan, Garnier & Co is headquartered in London, with additional offices in Paris, Munich and New York. The firm is a member of the London Stock Exchange and Euronext.

(www.bryangarnier.com)


Healthcare

Healthcare market update - September 2017

In our latest healthcare sector report, we highlight the key issues in the market during the month of September: major announcements concerning CAR-T technology, the first commercial breakthrough for gene therapy in the US and an unexpected pick-up of M&A activity in the diagnostics segment.

Click here to download the report >>